Checkpoint Therapeutics (NASDAQ:CKPT – Free Report) had its price objective lowered by HC Wainwright from $34.00 to $20.00 in a research report released on Monday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.
Checkpoint Therapeutics Stock Performance
Shares of CKPT stock opened at $2.11 on Monday. The stock’s 50-day simple moving average is $2.22 and its 200-day simple moving average is $1.98. The firm has a market capitalization of $75.30 million, a PE ratio of -0.76 and a beta of 1.25. Checkpoint Therapeutics has a fifty-two week low of $1.30 and a fifty-two week high of $3.62.
Insider Activity
In other news, CEO James F. Oliviero III sold 24,610 shares of the stock in a transaction dated Wednesday, June 26th. The stock was sold at an average price of $2.05, for a total value of $50,450.50. Following the transaction, the chief executive officer now directly owns 1,977,170 shares of the company’s stock, valued at $4,053,198.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CFO William Garrett Gray sold 13,038 shares of the company’s stock in a transaction dated Wednesday, June 26th. The stock was sold at an average price of $2.06, for a total value of $26,858.28. Following the sale, the chief financial officer now owns 672,186 shares in the company, valued at $1,384,703.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO James F. Oliviero III sold 24,610 shares of the company’s stock in a transaction dated Wednesday, June 26th. The stock was sold at an average price of $2.05, for a total value of $50,450.50. Following the completion of the sale, the chief executive officer now owns 1,977,170 shares in the company, valued at approximately $4,053,198.50. The disclosure for this sale can be found here. Corporate insiders own 2.10% of the company’s stock.
Institutional Trading of Checkpoint Therapeutics
About Checkpoint Therapeutics
Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.
Further Reading
- Five stocks we like better than Checkpoint Therapeutics
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Brinker International’s Price Dip is an Appetizing Entry Point
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- 3 Stocks That Could Beat the September Blues
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Canopy Growth Stock: Can It Sustain Recent Gains?
Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.